Log in

NYSE:ANVS - Annovis Bio Stock Price, Forecast & News

$4.79
-0.63 (-11.62 %)
(As of 02/27/2020 03:55 AM ET)
Today's Range
$4.73
Now: $4.79
$5.88
50-Day Range N/A
52-Week Range
$4.73
Now: $4.79
$10.61
Volume80,446 shs
Average Volume213,887 shs
Market Capitalization$31.22 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Annovis Bio, Inc., a clinical stage drug platform company, focuses on developing compounds to address neurodegeneration. The company's lead compound is ANVS-401, which is in Phase 2a clinical trials for the treatment of chronic neurodegenerative diseases, such as Down syndrome, Alzheimer's disease (AD), and Parkinson's disease. It is also developing ANVS-301, a compound in Phase 1 clinical trials to increase cognitive capability in later stages of AD and dementia; and ANVS-405, which is in preclinical study for protecting the brain after traumatic brain injury and/or stroke. Annovis Bio, Inc. was formerly known as QR Pharma, Inc. and changed its name to Annovis Bio, Inc. in March 2019. The company was founded in 2008 and is based in Berwyn, Pennsylvania.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone610-727-3913

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees2
Market Cap$31.22 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ANVS News and Ratings via Email

Sign-up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter.


Annovis Bio (NYSE:ANVS) Frequently Asked Questions

What is Annovis Bio's stock symbol?

Annovis Bio trades on the New York Stock Exchange (NYSE) under the ticker symbol "ANVS."

Has Annovis Bio been receiving favorable news coverage?

Media coverage about ANVS stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Annovis Bio earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Annovis Bio.

Who are some of Annovis Bio's key competitors?

What other stocks do shareholders of Annovis Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Annovis Bio investors own include Aptinyx (APTX), Edesa Biotech (EDSA), La Jolla Pharmaceutical (LJPC), vTv Therapeutics (VTVT), Alibaba Group (BABA), Amyris (AMRS), Advanced Micro Devices (AMD), Affimed (AFMD), Aethlon Medical (AEMD) and Adverum Biotechnologies (ADVM).

Who are Annovis Bio's key executives?

Annovis Bio's management team includes the folowing people:
  • Dr. Maria L. Maccecchini, Founder, CEO, Pres & Director (Age 69)
  • Mr. Jeffrey B. McGroarty CPA, Chief Financial Officer (Age 51)
  • Dr. Jeffrey L. Cummings, Chief Medical Officer & Member of Scientific Advisory Board (Age 70)
  • Dr. William C. Mobley, Chief Scientific Advisor & Member of Scientific Advisory Board

When did Annovis Bio IPO?

(ANVS) raised $10 million in an initial public offering (IPO) on Wednesday, January 29th 2020. The company issued 1,400,000 shares at a price of $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) acted as the underwriter for the IPO.

When does Annovis Bio's quiet period expire?

Annovis Bio's quiet period expires on Monday, March 9th. Annovis Bio had issued 2,000,000 shares in its public offering on January 29th. The total size of the offering was $12,000,000 based on an initial share price of $6.00. During Annovis Bio's quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Annovis Bio?

Shares of ANVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Annovis Bio's stock price today?

One share of ANVS stock can currently be purchased for approximately $4.79.

How big of a company is Annovis Bio?

Annovis Bio has a market capitalization of $31.22 million. Annovis Bio employs 2 workers across the globe.View Additional Information About Annovis Bio.

What is Annovis Bio's official website?

The official website for Annovis Bio is http://www.annovisbio.com/.

How can I contact Annovis Bio?

Annovis Bio's mailing address is 1055 WESTLAKES DRIVE SUITE 300, BERWYN PA, 19312. The company can be reached via phone at 610-727-3913 or via email at [email protected]


MarketBeat Community Rating for Annovis Bio (NYSE ANVS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  5 (Vote Outperform)
Underperform Votes:  6 (Vote Underperform)
Total Votes:  11
MarketBeat's community ratings are surveys of what our community members think about Annovis Bio and other stocks. Vote "Outperform" if you believe ANVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel